Bausch Health (NYSE:BHC) announced today that it initiated a clinical trial program in Canada to investigate the use of Virazole for treating COVID-19. With today’s announcement, Bausch joins Eli Lilly (NYSE:LLY) and Care Access Research, which both announced clinical testing of coronavirus therapies last week. Bausch’s Virazole is currently approved in the U.S. and Canada, among other […]
bauschhealth
Clearside Biomedical inks $76m licensing deal with Bausch for Xipere
Clearside Biomedical (NSDQ:CLSD) said yesterday that it entered into a license agreement with Bausch Health Ireland (NYSE:BHC) worth up to $76 million for the Xipere device for the treatment of macular edema associated with uveitis. The agreement grants Bausch an exclusive license to develop, manufacture, distribute, promote, market and commercialize the suprachoroidal injection device. Get the full […]
Bausch Health slashes Q1 losses, raises outlook
Shares in Bausch Health (NYSE:BHC) got a bump today when the company reported a drastic reduction in first-quarter losses and raised its outlook for the rest of the year. Laval, Quebec-based Bausch reduced its losses by -98.0% to -$52.0 million, or -15¢ per share, on sales growth of 1.1% to $2.02 billion for the three months […]
Bausch closes $1.5B debt offering, note redemption
Bausch Health (NYSE:BHC) said late last week that it closed a $1.5 billion offering of senior notes with funds raised slated to support the repurchasing of previously offered senior notes. The Quebec-based company said it closed an offering of $500 million in 5.75% senior secured notes due 2027 and that its Bausch Health Americas business, […]
